Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria.
Department of Internal Medicine, General Hospital Kufstein, Kufstein, Austria.
Ann Rheum Dis. 2014 Aug;73(8):1529-36. doi: 10.1136/annrheumdis-2012-203073. Epub 2013 Jun 5.
To investigate the association between psoriatic arthritis (PsA)-specific clinical composite scores and ultrasound-verified pathology as well as comparison of clinical and ultrasound definitions of remission.
We performed a prospective study on 70 consecutive PsA patients. Clinical assessments included components of Disease Activity Index for Psoriatic Arthritis (DAPSA) and the Composite Psoriatic Disease Activity Index (CPDAI). Minimal disease activity (MDA) and the following remission criteria were applied: CPDAI joint, entheses and dactylitis domains (CPDAI-JED)=0, DAPSA≤3.3, Boolean's remission definition and physician-judged remission (rem-phys). B-mode and power Doppler (PD-) ultrasound findings were semiquantitatively scored at 68 joints (evaluating synovia, peritendinous tissue, tendons and bony changes) and 14 entheses. Ultrasound remission and minimal ultrasound disease activity (MUDA) were defined as PD-score=0 and PD-score ≤1, respectively, at joints, peritendinous tissue, tendons and entheses.
DAPSA but not CPDAI correlated with B-mode and PD-synovitis. Ultrasound signs of enthesitis, dactylitis, tenosynovitis and perisynovitis were not linked with clinical composites. Clinical remission or MDA was observed in 15.7% to 47.1% of PsA patients. Ultrasound remission and MUDA were present in 4.3% and 20.0% of patients, respectively. Joint and tendon-related PD-scores were higher in patients with active versus inactive disease according to CPDAI-JED, DAPSA, Boolean's and rem-phys, whereas no difference was observed regarding enthesitis and perisynovitis. DAPSA≤3.3 (OR 3.9, p=0.049) and Boolean's definition (OR 4.6, p=0.03) were more useful to predict MUDA than other remission criteria.
PsA-specific composite scores partially reflect ultrasound findings. DAPSA and Boolean's remission definitions better identify MUDA patients than other clinical criteria.
研究银屑病关节炎(PsA)特异性临床综合评分与超声验证病理学之间的关系,以及临床和超声缓解定义的比较。
我们对 70 例连续的 PsA 患者进行了前瞻性研究。临床评估包括银屑病关节炎疾病活动指数(DAPSA)的组成部分和复合银屑病疾病活动指数(CPDAI)。采用最小疾病活动度(MDA)和以下缓解标准:CPDAI 关节、附着点和指(趾)炎域(CPDAI-JED)=0,DAPSA≤3.3,布尔的缓解定义和医生判断的缓解(rem-phys)。在 68 个关节(评估滑膜、肌腱周围组织、肌腱和骨变化)和 14 个附着点上对 B 型和功率多普勒(PD-)超声表现进行半定量评分。将关节、肌腱周围组织、肌腱和附着点的 PD 评分=0 和 PD 评分≤1 分别定义为超声缓解和最小超声疾病活动度(MUDA)。
DAPSA 但不是 CPDAI 与 B 型和 PD 滑膜炎相关。附着点炎、指(趾)炎、腱鞘炎和滑膜炎的超声征象与临床综合评分无关。根据 CPDAI-JED、DAPSA、布尔和 rem-phys,15.7%至 47.1%的 PsA 患者出现临床缓解或 MDA。分别有 4.3%和 20.0%的患者出现超声缓解和 MUDA。根据 CPDAI-JED、DAPSA、布尔和 rem-phys,与活动性疾病相比,关节和肌腱相关的 PD 评分在患有活动性疾病的患者中更高,而在附着点炎和滑膜炎中没有差异。与其他缓解标准相比,DAPSA≤3.3(OR 3.9,p=0.049)和布尔的定义(OR 4.6,p=0.03)更有助于预测 MUDA。
PsA 特异性综合评分部分反映了超声发现。与其他临床标准相比,DAPSA 和布尔的缓解定义能更好地识别 MUDA 患者。